Calvo, Pilar
PharmaMar S.A.,
Spain
2025 Rank: 357428
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Nanoscience & Nanotechnology
Rank in SubField 1: 3016 out of 157499 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 357428 | 389256 |
| Total Cites | 264 | 269 |
| H-index | 8 | 8 |
| Hm-index | 2 | 3 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 14 | 14 |
| Total Cites to Single+First Authored Papers | 170 | 171 |
| Number of Single+First+Last Authored Papers | 14 | 14 |
| Total Cites to Single+First+Last Authored Papers | 170 | 171 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 236 | 239 |
| Ratio of Total Citations to Distinct Citing Papers | 1.12 | 1.13 |
| Self-Citation Percentage |
1.86%
|
|
Calvo, Pilar
PharmaMar S.A.,
Spain
2024 Rank: 299881
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Nanoscience & Nanotechnology
Rank in SubField 1: 2461 out of 148458 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 299881 | 339315 |
| Total Cites | 273 | 275 |
| H-index | 8 | 8 |
| Hm-index | 2 | 3 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 14 | 14 |
| Total Cites to Single+First Authored Papers | 189 | 189 |
| Number of Single+First+Last Authored Papers | 14 | 14 |
| Total Cites to Single+First+Last Authored Papers | 189 | 189 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 243 | 245 |
| Ratio of Total Citations to Distinct Citing Papers | 1.12 | 1.12 |
| Self-Citation Percentage |
0.73%
|
|
Calvo, Pilar
PharmaMar S.A.,
Spain
2023 Rank: 308618
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Nanoscience & Nanotechnology
Rank in SubField 1: 2561 out of 140593 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 308618 | 322764 |
| Total Cites | 276 | 282 |
| H-index | 8 | 9 |
| Hm-index | 2 | 3 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 14 | 14 |
| Total Cites to Single+First Authored Papers | 187 | 188 |
| Number of Single+First+Last Authored Papers | 14 | 14 |
| Total Cites to Single+First+Last Authored Papers | 187 | 188 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 254 | 260 |
| Ratio of Total Citations to Distinct Citing Papers | 1.09 | 1.08 |
| Self-Citation Percentage |
2.13%
|
|
Calvo, Pilar
Research Department,
Spain
2022 Rank: 194264
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Nanoscience & Nanotechnology
Rank in SubField 1: 1527 out of 134745 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 194264 | 216346 |
| Total Cites | 344 | 356 |
| H-index | 10 | 10 |
| Hm-index | 3 | 3 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 14 | 14 |
| Total Cites to Single+First Authored Papers | 227 | 228 |
| Number of Single+First+Last Authored Papers | 14 | 14 |
| Total Cites to Single+First+Last Authored Papers | 227 | 228 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 298 | 308 |
| Ratio of Total Citations to Distinct Citing Papers | 1.15 | 1.16 |
| Self-Citation Percentage |
3.37%
|
|
Calvo, Pilar
Research Department,
Spain
2021 Rank: 196846
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Nanoscience & Nanotechnology
Rank in SubField 1: 1529 out of 131063 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 196846 | 217301 |
| Total Cites | 517 | 534 |
| H-index | 12 | 13 |
| Hm-index | 3 | 4 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 14 | 14 |
| Total Cites to Single+First Authored Papers | 346 | 348 |
| Number of Single+First+Last Authored Papers | 14 | 14 |
| Total Cites to Single+First+Last Authored Papers | 346 | 348 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 456 | 472 |
| Ratio of Total Citations to Distinct Citing Papers | 1.13 | 1.13 |
| Self-Citation Percentage |
3.18%
|
|
Calvo, Pilar
Research Department,
Spain
2020 Rank: 194402
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Pharmacology & Pharmacy
SubField 2:
Nanoscience & Nanotechnology
Rank in SubField 1: 1372 out of 94611 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 194402 | 207221 |
| Total Cites | 409 | 423 |
| H-index | 9 | 10 |
| Hm-index | 3 | 3 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 14 | 14 |
| Total Cites to Single+First Authored Papers | 266 | 267 |
| Number of Single+First+Last Authored Papers | 14 | 14 |
| Total Cites to Single+First+Last Authored Papers | 266 | 267 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 355 | 366 |
| Ratio of Total Citations to Distinct Citing Papers | 1.15 | 1.16 |
| Self-Citation Percentage |
3.31%
|
|
Related Profiles
Featured Profiles
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.